Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644286 | 0.75 | PLCG1 (0.41) | MAOAHPGDNOTUMPLCG1LMNA | |
| SCHEMBL10197082 | 0.72 | PLCG1 (0.39) | MAOAHPGDNOTUMPLCG1LMNA | |
| SCHEMBL10159164 | 0.70 | MAOA (0.49) | MAOAHPGDNOTUMALDH1A1KMT2A | |
| SCHEMBL10159177 | 0.67 | NOTUM (0.46) | HPGDNOTUMALDH1A1PLCG1LMNA | |
| SCHEMBL290638 | 0.65 | MAOA (0.54) | MAOALMNAKMT2AUSP2MEN1 | |
| SCHEMBL29958223 | 0.65 | MAOA (0.54) | MAOALMNAKMT2AUSP2MEN1 | |
| SCHEMBL29844652 | 0.65 | MAOA (0.54) | MAOALMNAKMT2AUSP2MEN1 | |
| Water SCHEMBL7420168 | 0.63 | MAOA (0.53) | MAOALMNAKMT2AUSP2MEN1 | |
| SCHEMBL9001235 | 0.63 | NOTUM (0.50) | MAOAHPGDNOTUMPLCG1LMNA | |
| SCHEMBL61667 | 0.62 | CA1 (0.47) | PLCG1KMT2AMEN1MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8263764-B2 | IL-12 Modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7863270-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2007050980-A2 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MAOA 1835/4885HPGD 424/4885NOTUM 1010/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAOA 4125/4885HPGD 4288/4885NOTUM 3788/4885 |
| US-20110294798-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IL15 | MAOA 2199/4885HPGD 51/4885NOTUM 4327/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MAOA 2457/4885HPGD 768/4885NOTUM 4406/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAOA 4125/4885HPGD 4288/4885NOTUM 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.